📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Metropolis Healthcare Sets March 20 as Record Date for 3:1 Bonus Issue
Metropolis Healthcare Limited has finalized March 20, 2026, as the record date for its 3:1 bonus share issuance. Shareholders holding the stock on this date will be eligible to receive three additional fully paid-up equity shares for every one share they currently own. This corporate action follows the board's recommendation in February 2026 and recent shareholder approval. The deemed date for the allotment of these new shares is scheduled for March 23, 2026.
Key Highlights
Bonus issue ratio confirmed at 3:1 (3 new shares for every 1 existing share)
Record date for eligibility fixed as Friday, March 20, 2026
Deemed date of allotment for bonus shares is Monday, March 23, 2026
Face value of shares remains unchanged at INR 2 per equity share
💼 Action for Investors
Existing shareholders should hold their positions through the record date to qualify for the bonus; note that the share price will adjust downward proportionally on the ex-date. Potential investors should monitor the ex-date to understand the impact on liquidity and price per share.
Metropolis Q3 FY26: 26% Revenue Growth and 3:1 Bonus Issue Announcement
Metropolis Healthcare reported a strong 26% year-on-year group revenue growth for Q3 FY26, with organic revenue increasing by 15%. A significant highlight is the Board's approval of a 3:1 bonus issue, aimed at rewarding shareholders and improving stock liquidity. Management maintained its FY26 organic growth guidance of 12-13% and expects margin expansion driven by the in-housing of high-margin genomics tests. The company is also seeing positive results from its strategic shift toward high-quality B2B and institutional partnerships.
Key Highlights
Group revenue increased by 26% YoY in Q3 FY26, while organic revenue grew by 15% YoY.
Board approved a 3:1 bonus issue (3 fully paid-up shares for every 1 existing share).
Organic patient volumes grew by 9% YoY, supported by a 15% growth in the B2C segment.
Core Diagnostics is expected to achieve high single-digit EBITDA margins in Q4 FY26 following the launch of in-house genomics testing.
Maintained FY26 organic revenue growth guidance of 12-13% with an outlook for expanded margins.
💼 Action for Investors
Investors should take note of the 3:1 bonus issue as a sign of management confidence and monitor the scaling of the new Centre of Genomics for margin improvements. The steady organic growth and successful integration of acquisitions suggest a robust long-term trajectory.
Metropolis Healthcare Announces 3:1 Bonus Issue; Seeks Shareholder Approval
Metropolis Healthcare has initiated a postal ballot process to seek shareholder approval for a 3:1 bonus share issue. Under this proposal, shareholders will receive three new fully paid-up equity shares of ₹2 each for every one existing share held. The company intends to capitalize a sum not exceeding ₹31.10 crore from its securities premium, general reserves, or retained earnings. The e-voting period for this resolution is scheduled from February 7, 2026, to March 8, 2026, with final results expected by March 10, 2026.
Key Highlights
Proposed bonus issue in the ratio of 3:1 (3 new shares for every 1 existing share)
Total capitalization amount from reserves not to exceed ₹31.10 crore
Remote e-voting period set for February 7, 2026, to March 8, 2026
Record date for eligibility to be determined and announced following shareholder approval
Bonus shares will rank pari-passu in all respects with existing equity shares
💼 Action for Investors
Investors should monitor for the announcement of the 'Record Date' as the stock price will undergo a proportional adjustment on the ex-bonus date. While fundamentally value-neutral, the move is expected to improve the stock's liquidity and indicates management's confidence in the company's reserves.
Metropolis Q3FY26: Organic PAT Jumps 52% YoY; Group Revenue Up 26% to ₹406 Cr
Metropolis Healthcare reported a strong Q3FY26 with organic revenue growing 15% YoY to ₹371 Cr and Group revenue (including recent acquisitions) rising 26% to ₹406 Cr. Organic EBITDA margins expanded significantly by 280 bps to 25.0%, driven by operating leverage and productivity gains. The company witnessed robust volume growth with organic patient counts up 9% and test volumes up 8%. Strategic focus on high-value segments like TruHealth (wellness) and Specialty testing, which grew 25% and 16% respectively, continues to drive premiumization and higher realizations.
Key Highlights
Organic PAT surged 52% YoY to ₹48 Cr, while Group PAT grew 63% to ₹51 Cr
Organic EBITDA margin improved to 25.0%, up from 22.2% in the previous year
TruHealth (wellness) segment revenue grew 25% YoY, now contributing 19% of total revenue
Revenue Per Patient (RPP) increased by 6% YoY to ₹1,116, reflecting a shift toward premium tests
Network expanded to 219 labs and over 4,800 service points across approximately 750 towns
💼 Action for Investors
Investors should take note of the significant margin expansion and the successful integration of recent acquisitions like Core Diagnostics. The company's ability to drive volume growth while increasing revenue per patient through specialty testing makes it a strong play in the diagnostic sector.
Metropolis Q3FY26: PAT Surges 63% to ₹51 Cr, Revenue Up 26%; 3:1 Bonus Issue Announced
Metropolis Healthcare reported a strong performance for Q3FY26, with revenue growing 26% YoY to ₹406 crore. Profit After Tax (PAT) surged 63% YoY to ₹51 crore (excluding exceptional items), while EBITDA grew 32% to ₹95 crore. The growth was driven by a 14% increase in patient volumes and a significant 35% jump in B2B revenues. Additionally, the Board has approved a 3:1 bonus issue, reflecting management's confidence in the company's long-term growth trajectory.
Key Highlights
Revenue increased by 26% YoY to ₹406 crore, supported by a 14% growth in patient volumes.
PAT (excluding exceptional items) grew 63% YoY to ₹51 crore, while EBITDA rose 32% to ₹95 crore.
B2B segment outperformed with ~35% YoY growth, while TruHealth and Specialty portfolios grew 37% and 34% respectively.
Operational metrics improved with Revenue per Test (RPT) up 11% and Revenue per Patient (RPP) up 10% YoY.
The Board approved a 3:1 bonus issue of equity shares to reward shareholders.
💼 Action for Investors
Investors should view these results positively as the company shows strong execution in both B2B and B2C segments with expanding margins. The bonus issue and volume growth in Tier II/III cities suggest a robust outlook for the diagnostic major.
Metropolis Healthcare Announces 3:1 Bonus Issue and Q3 FY26 Results
Metropolis Healthcare has approved a significant 3:1 bonus issue, providing three new equity shares for every one share held by investors. For the quarter ended December 31, 2025, the company reported standalone revenue of ₹334.78 crore and a profit of ₹32.03 crore, showing growth over the previous year's ₹27.40 crore profit. The company is also streamlining operations by transferring its EQAS division to a wholly-owned subsidiary for ₹1.25 crore via a slump sale. Results were slightly impacted by a one-time exceptional charge of ₹7.96 crore related to the new Labour Code provisions.
Key Highlights
Approved a 3:1 bonus issue of equity shares of face value ₹2 each.
Standalone revenue from operations grew to ₹334.78 crore in Q3 FY26 from ₹296.88 crore in Q3 FY25.
Standalone PAT for the quarter stood at ₹32.03 crore, up 16.9% compared to ₹27.40 crore YoY.
Divested EQAS Division to a wholly-owned subsidiary for ₹1.25 crore to optimize business structure.
Recognized a non-recurring exceptional expense of ₹7.96 crore due to the implementation of new Labour Codes.
💼 Action for Investors
The 3:1 bonus issue is a positive signal of management's confidence in the company's long-term growth and liquidity. Investors should stay invested while monitoring the impact of recent acquisitions like DAPIC and Scientific Pathology on consolidated margins.
Metropolis Healthcare Announces 3:1 Bonus Issue and Reports Q3 FY26 Results
Metropolis Healthcare has recommended a massive 3:1 bonus issue, granting 3 new shares for every 1 held, subject to shareholder approval. For Q3 FY26, the company reported a standalone revenue of ₹334.78 crore, representing a 12.8% YoY growth, though performance was lower compared to the previous quarter. Net profit for the quarter stood at ₹32.03 crore, which was impacted by a one-time exceptional charge of ₹7.96 crore related to the implementation of new Labour Codes. Additionally, the board approved the slump sale of its EQAS business division to a wholly-owned subsidiary for ₹1.25 crore to streamline operations.
Key Highlights
Approved 3:1 bonus issue (3 equity shares for every 1 held) to increase liquidity.
Standalone Revenue from operations grew 12.8% YoY to ₹334.78 crore.
Net Profit stood at ₹32.03 crore, up 16.9% YoY but down 31.3% sequentially from Q2 FY26.
Recognized a non-recurring exceptional expense of ₹795.67 lakhs due to new Labour Code regulations.
Approved slump sale of the EQAS Division to a subsidiary for a consideration of ₹1.25 crore.
💼 Action for Investors
The 3:1 bonus issue is a significant positive for retail liquidity and reflects management's long-term confidence. While YoY growth remains healthy, investors should monitor the sequential dip in margins and the integration of recent acquisitions.
Metropolis Q3 Profit Rises 17% YoY to ₹32 Cr; Announces 3:1 Bonus Issue
Metropolis Healthcare reported a steady performance for Q3 FY26 with standalone revenue growing 12.7% YoY to ₹334.78 crore. Net profit for the quarter rose 16.9% YoY to ₹32.03 crore, even after accounting for a ₹7.96 crore exceptional item related to new Labour Code provisions. A significant highlight for shareholders is the recommendation of a 3:1 bonus issue, which will quadruple the share count. The company also announced an internal restructuring, moving its EQAS business to a wholly-owned subsidiary for ₹1.25 crore.
Key Highlights
Standalone Revenue from operations increased 12.7% YoY to ₹334.78 crore in Q3 FY26.
Net Profit grew 16.9% YoY to ₹32.03 crore, despite a sequential decline from Q2 FY26.
Board recommended a 3:1 bonus issue (3 new shares for every 1 existing share held).
Recognized an exceptional expense of ₹795.67 lakhs due to the impact of new Government Labour Codes.
9M FY26 revenue crossed the ₹1,000 crore mark, reaching ₹1,014.13 crore compared to ₹904.59 crore YoY.
💼 Action for Investors
The 3:1 bonus issue is a strong positive signal for retail liquidity and reflects management's confidence in long-term growth. Investors should maintain a positive outlook while monitoring the resolution of pending income tax appeals involving ₹38.80 crore.
Metropolis Launches Centre of Genomics; Plans Expansion to 500+ Advanced Tests
Metropolis Healthcare has launched its 'Centre of Genomics' to scale precision diagnostics and genomic research in India. The facility is equipped with Illumina’s NovaSeq™ X Series, which can generate over 20,000 whole genomes annually, doubling the throughput of previous systems. Currently offering 220+ validated genomic tests, the company plans to expand this portfolio to over 500 assays within the next two to three years. This strategic move targets high-margin segments like oncology, neurology, and rare diseases while positioning the company for global clinical trial partnerships.
Key Highlights
Launched Centre of Genomics supported by two CAP-accredited labs in Mumbai and Delhi NCR.
Deployed Illumina’s NovaSeq™ X Series technology capable of 20,000+ whole genomes per year.
Current portfolio of 220+ genomic tests to be expanded to 500+ assays in the next 2-3 years.
Focuses on high-impact clinical areas including oncology, reproductive health, and transplant immunology.
Positioning as a strategic partner for global pharmaceutical programs and companion diagnostics.
💼 Action for Investors
This expansion into high-end genomics is a margin-accretive move that enhances Metropolis's competitive edge in specialized diagnostics. Investors should watch for improvements in Average Revenue Per Patient (ARPP) as these high-value tests gain traction.
Metropolis Reports Strong 26% YoY Revenue Growth in Q3FY26 Business Update
Metropolis Healthcare delivered a robust 26% YoY consolidated revenue growth for Q3FY26, driven by wellness and specialty testing. The TruHealth wellness segment grew by 35%, while the specialty segment saw a 33% increase, reflecting a shift towards high-end diagnostics. B2B revenues surged by 37%, significantly aided by the integration of Core Diagnostics and other recent acquisitions. Despite Q3 being a seasonally weak period, the company reported EBITDA margin expansion, showcasing strong operating leverage and successful integration of acquired entities.
Key Highlights
Consolidated revenue grew by approximately 26% YoY, including contributions from recent acquisitions like Core Diagnostics.
TruHealth Wellness and Specialty segments recorded strong YoY growth of 35% and 33% respectively.
B2B revenue growth stood at 37% YoY, while B2C revenue grew by 18% YoY on a consolidated basis.
Standalone EBITDA margins expanded YoY despite the quarter being seasonally weaker for the diagnostic industry.
Integration of acquisitions like DAPIC and Scientific Pathology is delivering operational efficiencies and outperforming average margins.
💼 Action for Investors
Investors should view this as a strong performance indicator, particularly the margin expansion and high-growth specialty segments. Monitor the upcoming detailed financial results for specific profit figures and management guidance on sustaining this momentum.